Correction of anemia with epoetin alfa in chronic kidney disease.
By Ajay K. Singh, L. Szczech, K. Tang, H. Barnhart, Shelly Sapp, M. Wolfson, D. Reddan. New England Journal of Medicine, 2006
2,529 citations recorded by the source corpus.
Subfields: Genetics, Hematology, Immunology
View Paper: https://www.semanticscholar.org/paper/9a547b7d8cc038d2074bdb163ae9045f54851e3b
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Genetics
Citations in the corpus
- Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle? (2008, background): “trolled trials have consistently shown no survival benefit from multiple new treatment strategies, such as increased dialysis dose (2,3), intensified nutrition (4), homocysteine-lowering therapy (5), normalization of hemoglobin with erythropoietin (6,7), lipid lowering with statins (8), and treatmen”
- Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). (2011, background): “Erythropoiesis-stimulating agents and/ or intravenous iron(107) may improve exercise tolerance but are without survival benefit.(108,109) Control of calcium and phosphate concentrations is instrumental in minimizing vessel calcification.”